Relationship between the inoculum dose of Streptococcus pneumoniae and pneumonia onset in a rabbit model

European Respiratory Journal

Volumn 25, Issue 4, 2005, Pages 693-700

  Yershov, Andrey L ^a   Jordan, B S ^a   Guymon, C H ^a   Dubick, M A ^a  

^a US ARMY INSTITUTE OF SURGICAL RESEARCH   (United States)

Author keywords

Experimental pneumonia; Inoculum dose; Rabbits; Streptococcus pneumoniae

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL TRANSMISSION; BACTERIUM ISOLATE; COLONY FORMING UNIT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; HISTOPATHOLOGY; HOST RESISTANCE; INOCULATION; LOBAR PNEUMONIA; LOGISTIC REGRESSION ANALYSIS; MALE; MICROSCOPY; MORBIDITY; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RABBIT; RISK FACTOR; SCORING SYSTEM; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; MALE; PNEUMOCOCCAL INFECTIONS; RABBITS; STREPTOCOCCUS PNEUMONIAE;

EID: 17244377305     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.05.00091904     Document Type: Article

References (32)

1. Singer ME, Harding I, Jacobs MR, Jaffe DH. Impact of antimicrobial resistance on health outcomes in the out-patient treatment of adult community-acquired pneumonia: a probability model. J Antimicrob Chemother 2003; 51: 1269-1282.
2. Bartlett JG, Dowell SF, Mandell LA, File TM, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000; 31: 347-382.
3. Lave JR, Lin CJ, Fine MJ, Hughes-Cromwick P. Cost of treating patients with community-acquired pneumonia. Semin Respir Crit Care Med 1999; 20: 189-197.
4. Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med 1995; 333: 1618-1624.
5. Lynch JP 3rd. Community-acquired pneumonia: risk factors and specific causes. J Respir Dis 2000; 21: 457-468.
6. Chen DK, McGeer A, de Azavedo JC, Low DE, for the Canadian Bacterial Surveillance Network. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 1999; 341: 233-239.
7. Piroth L, Martin L, Coulon A, et al. Development of a new experimental model of penicillin-resistant Streptococcus pneumoniae pneumonia and amoxicillin treatment by reproducing human pharmacokinetics. Antimicrob Agents Chemother 1999; 43: 2484-2492.
8. Charles PE, Piroth L, Desbiolles N, et al. New model of ventilator-associated pneumonia in immunocompetent rabbits. Crit Care Med 2002; 30: 2278-2283.
9. Brito DA, Ramirez M, de Lencastre H. Serotyping Streptococcus pneumoniae by multiplex PCR. J Clin Microbiol 2003; 41: 2378-2384.
10. Neeleman C, Geelen SP, Aerts PC, et al. Resistance to both complement activation and phagocytosis in type 3 pneumococci is mediated by the binding of complement regulatory protein factor H. Infect Immun 1999; 67: 4517-4524.
11. National Research Council. Guide for the Care and Use of Laboratory Animals. 7th Edn. Washington, DC, National Academy Press, 1996.
12. Rijneveld AW, Levi M, Florquin S, Speelman P, Carmeliet P, van Der Poll T. Urokinase receptor is necessary for adequate host defense against pneumococcal pneumonia. J Immunol 2002; 168: 3507-3511.
13. Dennesen PJ, van der Ven AJ, Kessels AG, Ramsay G, Bonten MJ. Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. Am J Respir Crit Care Med 2001; 163: 1371-1375.
14. Luna CM, Blanzaco D, Niederman MS, et al. Resolution of ventilator-associated pneumonia: prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome. Crit Care Med 2003; 31: 676-682.
15. Marquette CH, Copin MC, Wallet F, et al. Diagnostic tests for pneumonia in ventilated patients: prospective evaluation of diagnostic accuracy using histology as a diagnostic gold standard. Am J Respir Crit Care Med 1995; 151: 1878-1888.
16. Corley DE, Kirtland SH, Winterbauer RH, et al. Reproducibility of the histologic diagnosis of pneumonia among a panel of four pathologists: analysis of a gold standard. Chest 1997; 112: 458-465.
17. Ellbogen MH, Olsen KM, Gentry-Nielsen MJ, Preheim LC. Efficacy of liposome-encapsulated ciprofloxacin compared with ciprofloxacin and ceftriaxone in a rat model of pneumococcal pneumonia. J Antimicrob Chemother 2003; 51: 83-91.
18. Nseir S, Marquette CH. Diagnosis of hospital-acquired pneumonia: postmortem studies. Infect Dis Clin North Am 2003; 17: 707-716.
19. Heaney LG, Stevenson EC, Turner G, et al. Investigating paediatric airways by non-bronchoscopic lavage: normal cellular data. Clin Exp Allergy 1996; 26: 799-806.
20. Koch AL. Growth measurements. In: Gerhardt P, Murray PGE, Costilow RN, et al., eds. Manual of Methods for General Bacteriology. Washington, DC, American Society for Microbiology, 1981; pp. 179-207.
21. Anon. Streptococci and related genera. In: Baron EJ, Peterson LR, Finegold SM, eds. Bailey and Scotts Diagnostic Microbiology. 9th Edn. St Louis, MO, Mosby, 1994; pp. 333-352.
22. Anon. AARC clinical practice guideline. Sampling for arterial blood gas analysis. American Association for Respiratory Care. Respir Care 1992; 37: 913-917.
23. Reed LJ, Muench HA. Simple method of estimating fifty per cent endpoints. Am J Hyg 1938; 27: 493-497.
24. Sackett DL, Haynes RB, Tugwell P. Clinical Epidemiology: a Basic Science for Clinical Medicine. Boston, MA, Little, Brown, 1985; pp. 82-83.
25. Torres A, el-Ebiary M, Padro L, et al. Validation of different techniques for the diagnosis of ventilator-associated pneumonia. Comparison with immediate postmortem pulmonary biopsy. Am J Respir Crit Care Med 1994; 149: 324-331.
26. Saladino RA, Stack AM, Fleisher GR, et al. Development of a model of low-inoculum Streptococcus pneumoniae intrapulmonary infection in infant rats. Infect Immun 1997; 65: 4701-4704.
27. Frevert CW, Matute-Bello G, Martin TR. Rabbit models of pneumonia, peritoneal sepsis, and lung injury. Methods Mol Biol 2000; 138: 319-330.
28. Nicolau DP, Onyeji CO, Zhong M, Tessier PR, Banevicius MA, Nightingale CH. Pharmacodynamic assessment of cefprozil against Streptococcus pneumoniae: implications for breakpoint determinations. Antimicrob Agents Chemother 2000; 44: 1291-1295.
29. Ferrer R, Artigas A. Clinical review: non-antibiotic strategies for preventing ventilator-associated pneumonia. Crit Care 2002; 6: 45-51.
30. Marquette C, Wallet F, Copin M, et al. Relationship between microbiologic and histologic features in bacterial pneumonia. Am J Respir Crit Care Med 1996; 154: 1784-1787.
31. Baker D. Natural pathogens of laboratory mice, rats, and rabbits and their effects on research. Clin Microbiol Rev 1998; 11: 231-266.
32. Di Filippo A, De Gaudio AR. Device-related infections in critically ill patients. Part II: prevention of ventilator-associated pneumonia and urinary tract infections. J Chemother 2003; 15: 536-542.